Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.
Once-daily treatment with viloxazine extended release, also known as SPN-812, is safe and effective in children aged 6–11 years with attention-deficit/hyperactivity disorder (ADHD), yielding rapid improvements in symptoms and function, according to the results of a phase III trial.
Use of the prescription stimulant methylphenidate appears to also exert a positive effect on the lower urinary tract in children with attention deficit hyperactivity disorder (ADHD) but without voiding dysfunction, specifically increasing voided volume and bladder capacity, as shown in a study.
There is a high incidence of psychiatric comorbidities among gender nonconforming teenagers, with about two-thirds and one-third experiencing depression and anxiety, respectively, according to a study presented at ENDO 2020.
Adolescents with attention-deficit/hyperactivity disorder (ADHD) are likely to consume a greater amount of caffeine during later times of the day, which, in turn, is associated with sleep problems, a study has found.
Individuals with attention-deficit hyperactivity disorder (ADHD) are likely to exhibit suicidal behaviour, and this probability is further increased in the presence of comorbid psychiatric disorders, a recent study suggests.
An 8-week attention training programme using brain-computer interface (BCI) can help improve inattentive symptoms in children with attention deficit hyperactivity disorder (ADHD), thus providing a potential nonpharmacologic option for treating ADHD, a local study finds.
A novel device for trigeminal nerve stimulation (TNS) effectively improves attention deficit hyperactivity disorder (ADHD) symptoms in children aged 8–12 years, providing a safe nonmedication approach to treating ADHD, a recent study shows.
Use of memantine in the treatment of adults with attention deficit hyperactivity disorder (ADHD) appears to reduce symptoms associated with the condition, in addition to having a tolerable safety profile, a study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.